Elsevier

Biomaterials

Volume 32, Issue 21, July 2011, Pages 4914-4924
Biomaterials

Co-delivery of small interfering RNA and plasmid DNA using a polymeric vector incorporating endosomolytic oligomeric sulfonamide

https://doi.org/10.1016/j.biomaterials.2011.03.042Get rights and content

Abstract

Cationic polymers are potential intracellular carriers for small interfering RNA (siRNA). The short and rigid nature of an siRNA chain often results in larger and more loosely packed particles compared to plasmid DNA (pDNA) after complexing with carrier polycations, and in turn, poor silencing effects are seen against the target mRNAs. A helper polyanion, pDNA, was incorporated along with siRNA to form compact nanosized polyplexes. At C/A (cation/anion) ratios of 2 and 5, poly(l-lysine) (PLL)/siRNA-pGFP and PLL/siRNA-pGFP-OSDZ (oligomeric sulfadiazine (OSDZ) for endosomolysis) complexes produced particles 90–150 nm in size with a 15–45 mV surface charge, while PLL/siRNA complexes yielded particles 1–2 μm in size at the same C/A ratios. The PLL/siRNA-pGFP (C/A 2) complexes showed significantly higher specific gene silencing (50–90% vs. 10–25%) than the complexes formed at C/A 5. PLL/siRNA-pGFP-OSDZ (C/A 2) complexes improved the specific gene silencing (90%) more dramatically than PLL/siRNA-pGFP (C/A 2) complexes (50%), demonstrating a potential role for OSDZ. PLL/siRNA-pGFP-OSDZ (C/A 2) complexes sustained higher specific gene silencing compared with PLL/siRNA-pGFP (C/A 2) complexes. Other oligomeric sulfonamides (OSA) with varying pKa used in PLL/siRNA-pGFP-OSA complexes also caused effective gene silencing. The pGFP in the PLL/siRNA-pGFP complexes successfully expressed GFP protein without interfering with the siRNA. In conclusion, this study demonstrates that long pDNA helps effectively form nanosized siRNA particles and that OSA enhances specific gene silencing. In a single nucleic acid carrier formulation, co-delivery of siRNA and pDNA is feasible to maximize therapeutic effects or to include therapeutic or diagnostic functionalities.

Introduction

RNA interference (RNAi) has been recognized as a promising therapy to induce sequence-specific and post-transcriptional silencing via the cleavage of homologous mRNA [1], [2] to treat cancers, infectious diseases, and CNS diseases [1]. RNAi is most often mediated by short hairpin RNAs (shRNA) or small interfering RNAs (siRNA) [2]. The shRNA is expressed after nuclear delivery of shRNA-expressing plasmid DNA (pDNA) and the duration of shRNA expression depends on the use of viral or non-viral vectors [2], [3]. The transient expression of shRNA carried by non-viral vectors is strongly influenced by dilution of the vector following cell proliferation and by the stability of siRNA in the cytosol [2], [3]. The use of siRNA has several advantages over shRNA. siRNA delivery avoids the barrier of the nuclear membrane as it acts in the cytosol, unlike shRNA-expressing pDNA [2], [3]. More importantly, siRNA duplexes are readily available from various sources via custom or pre-designed siRNAs targeting a particular mRNA of interest.

As unaided delivery of naked siRNA is very limited due to its anionic nature and resulting low permeability to plasma membranes [2], [4], polymer-based (polyplex and polymersome) or lipid-based (lipoplex and liposome) non-viral vectors are often used to aid in siRNA delivery [2], [5], [6], [7], [8]. While lipoplexes often aggregate or are unstable over time [9], polymeric siRNA vectors are more attractive due to their chemical diversity and ease of modifications [4], [10] for cell targeting, endosomal escape [11], and cytosolic release [8], [12], [13] of siRNA.

However when cationic polymers are used, siRNA frequently results in more loosely condensed and larger complexed particles than are seen under similar complexing conditions when used for pDNA polyplexes of 100–200 nm in size. Along with size concerns for use in in vivo tests, these less stable polymeric siRNA polyplexes were prone to premature dissociation of siRNA from the counterpart polycation [14]. This is the result of the siRNA chain being short and rigid [14], unlike long and flexible pDNA. In general, the electrostatic strength between polycations and polyanions (here, nucleic acids) increases with higher molecular weights (MW) [14], [15]. These short siRNAs (usually duplexes of 21–23 nucleotides) may result in one hundredth of the electrostatic strength of pDNA (more than 2000 base pairs) in an association with a given polycation [16]. Thus, to form stable and nanoscale siRNA polyplexes, one should adopt higher molecular weight (MW) polymers or high polycation/siRNA ratios [10]. However, excess polycation induces polycation-mediated cytotoxicity [17]. Alternatively, siRNA can be elongated by concatemerization with sticky overhangs [16] or multimerization via chemical linkages [18]. To avoid off-target silencing effects of lengthy siRNAs, these multimeric siRNAs can be designed to be cleaved into monomeric siRNAs in the cytoplasm.

Instead of modifying siRNAs, some groups have incorporated polyanions as an additive [19], [20]. The Huang group added calf thymus DNA or hyaluronic acid (HA) when formulating siRNA polyplexes with protamine and then the siRNA/protamine/DNA (or HA) nanoparticles were encapsulated in liposomes [19], [20]. This strategy resulted in a particle size reduction by 10–30% and improved silencing efficiency 20–80% when compared with siRNA formulations without polyanion additives [5], [19], [20], [21].

In this study, polymer-based siRNA carriers were used to exclude the instability of liposome-based formulations. Poly (l-lysine) (PLL) was selected as a representative polycation. Oligomeric sulfonamides (OSA) with known endosomolytic activity that have been developed by our group [22] were also introduced into the PLL-based siRNA complexes. In addition, to enhance the stability of polymeric siRNA complexes as well as to examine the potential of including multiple therapeutics in a single drug carrier, a reporter pDNA was employed as a lengthy polyanion instead of calf thymus DNA or HA. This study aimed to elucidate how the addition of pDNA in PLL/siRNA-pDNA and PLL/siRNA-pDNA-OSA complexes modulates their physicochemical, biological, and therapeutic characteristics.

Section snippets

Materials and cell culture

Poly(l-lysine) hydrogen bromide (PLL∙HBr; MW 24 kDa), branched polyethyleneimine (bPEI; Mw 25 kDa, Mn 10 kDa), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), Dulbecco’s Modified Eagle’s Medium (DMEM), Ca2+-free and Mg2+-free Dulbecco’s phosphate buffered saline (DPBS), dimethyl sulfoxide (DMSO), 4-(2-hydroxy-ethyl)-1-piperazine (HEPES), d-glucose, sodium bicarbonate, ethidium bromide (EtBr), aphidicolin, heparin sodium salts (149 USP units/mg), 4′,6-diamidino-2-phenylindole

Physicochemical properties and transfection of PLL/siRNA complexes

Prior to the investigation of PLL/siRNA-pDNA complexes, the physicochemical and transfection properties of the PLL/siRNA complexes were studied as a reference. PLL was used to condense siRNA over a complexation range of 2 ≤ C/A (cation/anion) ≤ 20 (Fig. 1(A)). The PLL/siRNA complexes were retained well when run on an agarose gel. However, a weak EtBr intensity (approximately 10–20% of the EtBr intensity when EtBr is intercalated with all of the siRNA) from the polyplexes was still detected.

Conclusion

This study was designed to produce stable and dense nanocomplexes by complexing PLL with siRNA and pGFP at low C/A ratios. The resulting PLL/siRNA-pGFP complexes were compact and induced effective gene silencing. OSA-containing PLL/siRNA-pGFP complexes were better at inducing silencing than their OSA-free counterparts. In addition to silencing a target mRNA, the polyplexes were able to express GFP. Thus, the polyplexes investigated in this study may have the potential to silence an mRNA of

Acknowledgements

This work was partially supported by National Institutes of Health, USA (NIH GM82866).

References (35)

Cited by (70)

  • Stimuli-responsive nanoparticles based on poly acrylic derivatives for tumor therapy

    2021, International Journal of Pharmaceutics
    Citation Excerpt :

    Due to PTX desorption and release triggered by redox and thermal stimuli at tumor site, the micelles showed a preeminent capability to reduce cardiotoxicity and weight loss caused by PTX. Considering pH differences between physiological and extracellular in tumor tissues (pH 6.5–7.2) (Engin et al., 1995; Stubbs et al., 2000) and weak acidity in endosomal (pH 5.5–6.0)/lysosomal (pH 4.5–5.0) (Gao et al., 2010), numerous efforts have been directed to the exploration of pH-triggered nanocarriers (Chang Kang and Bae, 2011; Deirram et al., 2019). The weak acidic environment can protonate carboxyl groups and amines of PAA or derivatives, leading to shrinkage of hydrophilic part and destabilization of endosomal/lysosomal membrane following cargo release, which is termed as proton sponge effect (Kim et al., 2019a; Varkouhi et al., 2011; Yang et al., 2018; Zhou et al., 2011).

  • Calcium-mineralized polypeptide nanoparticle for intracellular drug delivery in osteosarcoma chemotherapy

    2020, Bioactive Materials
    Citation Excerpt :

    Generally, there are mainly two kinds of tumor acidity-sensitive drug delivery nanoplatforms prepared from polymers with exposed protonatable−deprotonizable groups [5] or pH-trigged linkages [6]. The protonatable groups in the acidic tumor microenvironments include amino [7], imidazolyl [8], sulfonamide [9], and carboxyl groups [10]. The protonation of the functional groups induces the swelling or shrinking of nanocarriers and accelerates the payload release when exposed to the acidic intratumoral or intracellular medium [11].

  • Advanced polymers for nonviral gene delivery

    2019, Nucleic Acid Nanotheranostics: Biomedical Applications
View all citing articles on Scopus
View full text